Related Experiment Video
Updated: Feb 11, 2026

Preparation of DNA-crosslinked Polyacrylamide Hydrogels
Published on: August 27, 2014
The evolving role of DNA inter-strand crosslinks in chemotherapy
Halley B Rycenga1, David T Long1
1Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC, USA.
Abstract:
DNA crosslinking agents make up a broad class of chemotherapy agents that target rapidly dividing cancer cells by disrupting DNA synthesis. These drugs differ widely in both chemical structure and biological effect. In cells, crosslinking agents can form multiple types of DNA lesions with varying efficiencies. Inter-strand crosslinks (ICLs) are considered to be the most cytotoxic lesion, creating a covalent roadblock to replication and transcription. Despite over 50 years in the clinic, the use of crosslinking agents that specialize in the formation of ICLs remains limited, largely due to high toxicity in patients. Current ICL-based therapeutics have focused on late-stage and drug-resistant tumors, or localized treatments that limit exposure. In this article, we review the development of clinical crosslinking agents, our understanding of how cells respond to different lesions, and the potential to improve ICL-based chemotherapeutics in the future.
Insights
DNA crosslinking agents disrupt cancer cell growth by damaging DNA. Improving inter-strand crosslink (ICL) therapies could reduce toxicity and enhance cancer treatment effectiveness.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- DNA crosslinking agents are chemotherapy drugs targeting rapidly dividing cancer cells.
- These agents induce various DNA lesions, with inter-strand crosslinks (ICLs) being highly cytotoxic.
- Current ICL-based therapies face limitations due to significant patient toxicity.
Purpose of the Study:
- To review the development of clinical DNA crosslinking agents.
- To explore cellular responses to different DNA lesions induced by these agents.
- To identify future strategies for improving ICL-based chemotherapeutics.
Main Methods:
- Review of existing clinical data and research on DNA crosslinking agents.
- Analysis of cellular mechanisms involved in DNA damage and repair.
- Examination of therapeutic strategies and their associated toxicities.
Main Results:
- ICLs represent a potent but toxic DNA lesion, limiting therapeutic applications.
- Cellular responses to DNA damage vary, influencing drug efficacy and toxicity.
- Over 50 years of clinical use highlight challenges in optimizing ICL agent therapy.
Conclusions:
- Further research into cellular responses is crucial for mitigating ICL agent toxicity.
- Developing novel strategies to enhance the therapeutic index of ICL agents is essential.
- Future advancements may lead to more effective and safer ICL-based cancer treatments.
More Related Videos
13:46Separation of Single-stranded DNA, Double-stranded DNA and RNA from an Environmental Viral Community Using Hydroxyapatite Chromatography
Published on: September 29, 2011
10:12Author Spotlight: Quantitative Detection of DNA Protein Crosslinks and Their Post-Translational Modifications
Published on: April 21, 2023
Related Concept Videos
Lagging Strand Synthesis
There are several major differences between synthesis of the leading strand and synthesis of the lagging strand. 1) Leading strand synthesis happens in the direction of replication fork opening, whereas lagging strand synthesis happens in the...
Single-Strand DNA Binding Proteins
DNA Helicases
Fixing Double-strand Breaks
DNA Replication
Replication in Prokaryotes
DNA replication...
DNA Topoisomerases
Types and Mechanism of action
Topoisomerases are divided into two main types. ...